文献速递乳腺癌放疗放疗物理与技术

动态对比增强与扩散加权磁共振成像用于单次消融新辅助部分乳腺照射后的疗效评估

Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation.
PubMed 文献 · Adv Radiat Oncol · 2021-11-20

研究纳入36例低危乳腺癌患者,在单次消融新辅助部分乳腺照射(NA-PBI)前及后1周、2、4、6个月行3.0T动态对比增强(DCE)与扩散加权(DW)MRI,评估半定量参数与影像学及病理学反应的关系。结果显示增强参数在1周时升高、2个月起下降,ADC从基线0.83×10⁻³ mm²/s升至6个月1.28×10⁻³ mm²/s;TTE、RE1min、%EV对影像学反应、TTE、RE1min、ADC对病理学反应最具区分潜力,但本探索性研究未能证明MRI参数与影像学及病理学反应之间的关系。

要点

  • 单次NA-PBI后1周增强参数升高(TTE 15s vs 10s;RE1min 161% vs 197%;%EV 47% vs 67%),2个月起下降。
  • 中位ADC从基线0.83×10⁻³ mm²/s升至6个月1.28×10⁻³ mm²/s。
  • TTE、RE1min、%EV对影像学反应、TTE、RE1min、ADC对病理学反应最具区分潜力。

核心结论

  • DCE与DW-MRI半定量分析显示NA-PBI后1周相对增强与ADC变化,提示急性炎症,2至6个月变化提示肿瘤消退。
  • 本探索性研究未能证明MRI参数与影像学及病理学反应之间的关系。

研究设计与样本

  • 分析36例接受单次消融NA-PBI的低危乳腺癌患者的3.0T DCE与DW-MRI,照射后6或8个月行保乳手术。
  • MRI于NA-PBI前及后1周、2、4、6个月采集,由乳腺放射科医师评估影像学反应、乳腺病理科医师评分病理学反应。
  • 患者按病理学反应分为反应者与无反应者(残留肿瘤细胞<10% vs ≥10%)。

主要发现

  • NA-PBI后1周增强普遍升高(基线 vs 1周中位TTE:15s vs 10s;RE1min:161% vs 197%;%EV:47% vs 67%)。
  • 自2个月起增强下降(6个月中位TTE:25s;RE1min:86%;%EV:12%)。
  • 中位ADC从基线0.83×10⁻³ mm²/s升至6个月1.28×10⁻³ mm²/s。
  • TTE、RE1min、%EV对影像学反应、TTE、RE1min、ADC对病理学反应最具区分潜力。

关键数值与推荐

  • 病理学反应分组阈值:残留肿瘤细胞<10%为反应者,≥10%为无反应者。
  • 评估的半定量MRI参数包括TTE、RE1min、%EV、washout曲线类型分布及ADC。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出本探索性研究未能证明MRI参数与影像学及病理学反应之间的关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. METHODS AND MATERIALS: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). RESULTS: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median - TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median - TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10-3 mm2/s at baseline to 1.28 × 10-3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. CONCLUSIONS: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Vasmel JE, Groot Koerkamp ML, Mandija S, et al. Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation. Adv Radiat Oncol. 2021. PMID: 35387418. doi:10.1016/j.adro.2021.100854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。